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Abstract
Background: With the advances in modern radiotherapy (RT), many patients with head and neck cancer (HNC)
can be effectively cured, and their health-related quality of life (HR-QoL) has become an important issue. In this
study, we evaluated the prognosticators of HR-QoL in a large cohort of HNC patients, with a focus on the result
from technological advances in RT.
Methods: A cross-sectional investigation was conducted to assess the HR-QoL of 640 HNC patients with cancer-
free survival of more than 2 years. Among them, 371 patients were treated by two-dimensional RT (2DRT), 127 by
three-dimensional conformal RT (3DCRT), and 142 by intensity-modulated RT (IMRT). The EORTC QLQ-C30
questionnaire and QLQ-H&N35 module were used. A general linear model multivariate analysis of variance was
used to analyze the prognosticators of HR-QoL.
Results: By multivariate analysis, the variables of gender, annual family income, tumor site, AJCC stage, treatment
methods, and RT technique were prognosticators for QLQ-C30 results, so were tumor site and RT technique for
H&N35. Significant difference (p < 0.05) of HR-QoL outcome by different RT techniques was observed at 2 of the
15 scales in QLQ-C30 and 10 of the 13 scales in H&N35. Compared with 2DRT, IMRT had significant better outcome
in the scales of global QoL, physical functioning, swallowing, senses (taste/smell), speech, social eating, social
contact, teeth, opening mouth, dry mouth, sticky saliva, and feeling ill.
Conclusions: The technological advance of RT substantially improves the head-and-neck related symptoms and
broad aspects of HR-QoL for HNC survivors.
Background
Health-related quality of life (HR-QoL) and its assess-
ment have become increasingly important in health
care, especially in the field of chronic diseases. Conven-
tionally, the endpoints of medical care for cancer
patients usually focused on the so-called survival rate,
local control rate, or complication rate. These endpoints
were usually assessed from the physician’sp o i n t so f
view. These assessments lacked knowledge and under-
standing of the patients’ mental and emotional well
being. HR-QoL generally refers to the patient’s percep-
tion of the effects of the disease and the impact on the
patient’s daily functioning, and has two fundamental
premises. First, it is a multi-dimensional survey incor-
porating physical, psychological, social, and emotional
functional domains. Second, it is subjective and must be
self-reporting, according to the patient’so w ne x p e r i -
ences [1].
Determining how to measure and quantify the subjec-
tive experience of HR-QoL has been a challenging issue.
There are now a variety of well-validated HR-QoL
instruments available for use in the field of oncology.
Three types of methods have been categorized. They
include the generic type, e.g. the Short Form-36 (SF-36),
the cancer specific type, e.g. the Functional Assessment
of Cancer Treatment (FACT-G), the European Organi-
zation of Research and Treatment of Cancer Quality of
Life Core Questionnaire, version 3.0 (EORTC QLQ-
C30), and the cancer site-specific type, e.g. the head and
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FACT (FACT-HN) [2-6].
Perhaps in no other group of cancer patients does
HR-QoL present as important a role as in HNC
patients. This is because they may have obviously debili-
tating problems with swallowing, speech, and hearing, as
well as the psychological effects of loss of function and
change in body image [7]. Radiotherapy is one of the
most important treatment modalities for HNC patients,
either in a definite way or a combination with surgery
and/or chemotherapy (C/T). Over the past decade, the
advances of RT techniques for treating HNC have
emerged from so-called two-dimensional RT (2DRT) to
the three-dimensional conformal RT (3DCRT) and
intensity-modulated RT (IMRT). 2DRT has proven
effective in the treatment of HNC. However, complica-
tions associated with irradiation of sensitive normal
structures, such as the salivary glands in the path of the
irradiation, are still remarkable and often lifelong. The
reliance of 3DCRT and IMRT on computed tomogra-
phy-guided 3D planning allows better delineation of
tumor target and organs at risk with clearer radiological
visualization of their spatial relations, thus providing a
potentially therapeutic benefit of dose escalation to
tumor tissue with reduced toxicity to normal tissues [8].
IMRT represents an advanced form of 3DCRT. It
employs inverse planning algorithms and iterative com-
puter-driven optimization to generate treatment fields
with varying beam intensity. Combinations of intensity-
modulated fields produce custom-tailored conformal
dose distributions around the tumor, with steep dose
gradients at the transition to adjacent normal tissues.
Growing reports have shown that the technical and
dosimetric superiority of 3DCRT and IMRT over 2DRT
can translate into clinical benefits, such as reduced nor-
mal tissue toxicity (e.g., parotid gland sparing), improved
local control, or even patient survival [9-14].
Radical RT for treating HNC was routinely delivered
by 2DRT in our hospital before the introduction of
3DCRT in April 1996. From April 1996 to March 2002,
3DCRT was gradually used to replace 2DRT. After
becoming familiar with the techniques of 3DCRT and
implementation of the IMRT system by March 2002,
the physicians and physicists in our institute began to
use the two techniques in treating HNC. In a previous
publication, we have reported that HNC survivors had
significantly poorer HR-QoL outcomes compared with
Taiwanese norms [15,16]. In this study, we further com-
pared the HR-QoL results assessed by the EORTC
QLQ-C30 and QLQ-H&N35 modules for HNC survi-
vors who, as a result of technological advances in RT at
our institute, were treated with 2DRT, 3DCRT, or
IMRT in different time periods.
Methods
Study population
This study is a cross sectional investigation, analyzing
HR-QoL data of HNC patients who were cancer free
when their HR-QoL was assessed during the period
from January 2005 to December 2008. Eligibility criteria
of patients included 1) pathologically proven HNC at
nasopharynx, oral cavity, oropharynx, hypopharynx, or
larynx, 2) receiving RT and regular follow-up at the
department of radiation oncology at Chang Gung Mem-
orial Hospital - Kaohsiung Medical Center, 3) cancer
free survival more than two years after RT, and 4) com-
pletion of the self-reported questionnaire. Six hundred
and forty HNC patients, treated with definite or post-
operative RT, were collected and informed consent was
obtained from all of them. They included 371 patients
treated by 2DRT and 269 patients by conformal RT
(3DCRT: 127 patients, IMRT: 142 patients). Concerning
the existence of selection bias, we compared the distri-
butions of sociodemographic characteristics (including
age, gender, marital status, and education level) between
HNC survivors in the study and all other surviving
HNC patients (n = 221) found in the cancer registry
database in the department. No statistically significant
differences were found between them (data not shown).
Patient characteristics including sociodemographic
variables and cancer- or treatment- related variables are
listed in Table 1. The cancer stages were according to
the staging system of the American Joint Committee on
Cancer (AJCC 6
th edition) published in 2002. The
comorbidity status was recorded according to the Charl-
son comorbidity index by review of chart and on the
basis of self-report [17]. A summary of the primary can-
cer site included 316 cases (49%) of nasopharyx, 129
(20%) of oral cavity, 75 (12%) of oropharynx, 75 (12%)
of hypopharynx, and 45 (7%) of larynx. As regards the
sociodemographic information, 86% of them were edu-
cated ≦12 years, 53% with an annual family income ≦1.2
million NTD (1USD = 33NTD), 65% not employed, and
19% without a spouse (unmarried or divorced). Four
hundred and thirty patients (67%) had AJCC stage III or
IV disease and 267 (42%) patients had at least one kind
of comorbidity. The major treatment was surgery in 249
(39%) patients and RT alone or plus C/T in 391 (61%)
patients. Uneven distribution existed between the 2DRT
and 3DCRT/IMRT group. The 3DCRT/IMRT group
had a higher distribution in patients with lower annual
family income, non-nasopharyngeal cancer site, stage
III-IV, surgery, chemotherapy, or shorter survival years.
The median (range) follow-up years of patients after
treatment when their HR-QoL data were collected were
5.2 (2.8-14.1), 3.9 (2.1-10.3), and 3.1 (2.0-6.5) years in
the 2DRT, 3DCRT, and IMRT group, respectively. This
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review boards (IRB) of the hospital.
Techniques of RT
2DRT
The detailed portal arrangement and dosing of conven-
tional 2DRT in HNC have been described previously
[18,19]. Briefly, 2DRT was given in two phases, namely
before and after 44~46.8 Gy of the spinal cord tolerance
dose. In the first phase, patients were irradiated by a 6-
MV photon beam with a daily fraction of 1.8 or 2.0 Gy
(5~6 fractions per week) via bilateral opposing faciocer-
vical fields and one lower anterior cervical field. For
definite RT, the target covers the primary tumor with
surrounding anatomic area and regional neck lympha-
tics. For postoperative cases, the surgical tumor and
nodal bed as well as the prophylactic risky nodal area
were included. In the second phase, the gross tumor
was boosted to 64.8~81 Gy in definite RT and tumor
bed to 57.6~64.8 Gy in postoperative cases via bilateral
opposing photon beams to shield the spinal cord. Resi-
dual neck lymph nodes or risky nodal bed area were
simultaneously boosted by a 9- or 12-Mev electron
beam to 56~79 Gy, depending on the nodal situation.
3DCRT
The immobilization, treatment targets, and dose/fractio-
nation prescription of 3DCRT in treating HNC in our
institute primarily followed the guidelines for 2DRT.
The Cadplan (Varian, Milpitas, CA) or Pinnacle 3D
treatment planning system (Pinnacle3, Philips, Fitch-
burg, WI) was used. The technical details of 3DCRT in
HNC have been addressed [19,20]. For each patient, 5
or 7 coplanar portals were usually designed. Shrinkage
of the clinical target volume (CTV) volume was usually
performed after the tumoricidal dose of 45.0-50.4 Gy
was reached for the microscopic lesions. The 90-95%
isodose volume to cover the planning target volume
(PTV) with the spinal cord strictly limited below the
60% isodose line was applied.
IMRT
The immobilization, target definition and delineation,
and dose/fractionation prescription of IMRT for
HNSCC treated by combined modality were approxi-
mately the same as described above for 3DCRT. We
used the Cadplan or Pinnacle treatment planning system
to perform the inverse planning and dose optimisation.
For each patient, IMRT plans with five or seven copla-
nar portals were created. The delivery of the plans was
performed in Varian machines equipped with dynamic
multi-leaf collimators. The dose/fractionation prescrip-
tion of IMRT primarily followed the guidelines for
3DRT [16,21].
Instruments of HR-QoL
The Taiwan Chinese versions of the EORTC QLQ-C30
and QLQ-H&N35 questionnaires were obtained from
the Quality of Life Unit, EORTC Data Center in Brus-
sels, Belgium [4,6,22]. The EORTC questionnaires were
chosen for this research because it is one of the most
widely implemented questionnaires, with over 10 years
of research invested to develop an integrated, modular
Table 1 Patient characteristics (n = 640)
Variables Total 2DRT 3DCRT IMRT
Patient number 640 371 127 142
Age, median (range) years 52
(15-87)
52
(15-87)
53
(31-83)
51
(23-79)
Male/female 537/103 297/74 117/10 123/19
Education years
≦6 245 147 52 46
6~12 305 168 64 73
>12 90 56 11 23
Annual family income, (104
NTD)
<60 119 53 30 36
60~120 218 125 47 46
≥ 120 303 193 50 60
Marital status
With spouse 518 298 102 118
Without spouse 122 73 25 24
Employment
Yes 225 139 36 50
No 415 232 91 92
Cancer sites
Nasopharynx 316 226 31 59
Oral cavity 129 64 33 32
Oropharynx 75 41 21 13
Hypoppharynx 75 20 28 27
Larynx 45 20 14 11
AJCC stage
I-II 210 145 26 39
III-IV 430 226 101 103
Radiation dose
≦70.2Gy 281 126 81 74
>70.2Gy 359 245 46 68
Surgery
No 391 264 53 74
Yes 249 107 74 68
Chemotherapy
No 343 237 57 49
Yes 297 134 70 93
Comorbidity score
0 373 219 66 88
≧1 267 152 61 54
Follow-up years, median 4.3 5.2 3.9 3.1
Abbreviations: RT = radiotherapy; 2DRT = two dimensional RT; 3DCRT = three
dimensional conformal RT; IMRT = intensity-modulated RT; 1USD = 33NTD;
AJCC = American Joint Committee on Cancer, 6th edition; Comorbidity score
was based on Charlson comorbidity index.
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international clinical trials, and the Taiwan Chinese ver-
sion is available and easily completed by our patients
[23]. The EORTC QLQ-C30 incorporates a range of
HR-QoL issues relevant to a broad range of cancer
patients. It has been translated into many languages and
validated for many types of cancer, including head-and-
neck cancer. It contains five functional scales (physical,
role, cognitive, emotional and social), three symptom
scales (fatigue, pain, and nausea/vomiting), a global QoL
scale, and six single-items (dyspnea, insomnia, appetite
loss, constipation, diarrhea, and financial difficulties).
T h eQ L Q - H & N 3 5i sam o d u l eu s e df o ra s s e s s i n gt h e
HR-QoL for head-and-neck cancer patients. It incorpo-
rates seven multiple-item scales that assess the symp-
toms of pain, swallowing ability, senses (taste/smell),
speech, social eating, social contact, and sexuality. Also
included are six single-item scales, which survey the pre-
sence of symptomatic problems associated with teeth,
mouth-opening, dry mouth (xerostomia), sticky saliva,
coughing, and feeling ill. All scales pertaining to the
EORTC QLQ-C30 and QLQ-H&N35 range from zero
to 100. A high score for a functional or global HR-QoL
scale represents a relatively high/healthy level of func-
tioning or global quality of life, whereas a high score for
a symptom scale represents the presence of a symptom
or problem(s).
Statistic analysis
The mean scores and standard deviations of the HR-
QoL scales were calculated according to the EORTC
QLQ scoring manual [24]. To analyze the correlations
between the factors and the HR-QoL scales, general lin-
ear model (GLM) multivariate analysis of variance
(MANOVA) was used [25]. The GLM-MANOVA
approach is used to test the hypothesis of a significant
association between a set of interrelated dependent vari-
ables (HR-QoL scales) and independent variables. The
independent variables analyzed in the present study con-
sisted of five sociodemographic variables: age (<40 v.
40~60 v. ≥ 60 years), sex (male v. female), years of edu-
cation years (≤6 v.6 ~ 1 2v. >12 years), marital status
(with v. without spouse), and annual family income
(<0.6 v. 0.6~1.2 v. ≥1.2 million NTD), and six clinical
factors: CCI score (0 v. ≥1), tumour site (Oral cavity v.
Oropharynx v. Hypopharynx/Larynx v.N a s o p h a r y n x ) ,
AJCC stage (stage I-II v. III-IV), treatment methods
(surgery + RT v. surgery + RT + C/T v.R T±C / T ) ,R T
technique (2DRT v.3 D C R Tv.I M R T ) ,a n df o l l o w - u p
years (2~3 v. 3~5 v. > 5).
GLM-MANOVA was performed for QLQ-C30 and
H&N35 separately and in the following two steps. First,
to investigate the association of a given factor with HR-
QoL scales, a univariate analysis was conducted to
establish whether the factor was associated significantly
with any of the HR-QoL scales. Wilks’ l was used to
test the impact of each variable included in the model.
All variables were entered into the multi-factor model.
In case of a significant association between a factor and
all HR-QoL scales taken together, a second ANOVA
was performed to investigate the association between
that prognostic factor and each HR-QoL scale sepa-
rately, with post-hoc testing using the Bonferroni
method with a p-value <0.05 from the two-sided test
regarded to be statistically significant.
Being the most concerned scales of HR-QoL in the
study, the global QoL and xerostomia were further ana-
lyzed by multiple linear regression models to explore
their associated prognosticators, respectively. All the
data processing was performed using the statistic soft-
ware SPSS for Windows (version 15.0; SPSS Inc., Chi-
cago, IL).
Results
Outcomes of HR-QoL
The mean score for global QoL was 54.6. The value of
the five scales of functioning ranged from 75.1 (social
functioning) to 86.4 (role functioning). The highest
symptom score on QLQ-C30 was for fatigue, followed
by financial problems and insomnia. In the H&N35
module, dry mouth, sticky saliva, and tooth problems
ranked as the three worst symptoms. (Table 2)
Variables associated with HR-QoL outcomes
In the first step of the GLM-MANOVA, the association
between the independent variables (five sociodemo-
graphic and six clinical variables) and the dependent
variables (15 scales of QLQ-C30) was investigated (one-
factor model, Table 3). This analysis showed that 10 of
the 11 variables (except the length of follow-up) (p <
0.05) were associated with the overall outcome on
QLQ-C30. The 11 variables were then entered into the
multifactor model analysis, which indicated that the
variables of gender, annual family income, tumor site,
AJCC stage, treatment methods, and RT technique
remained significant. The same statistical procedures
were repeated for the analysis of the association between
the 11 independent variables and the scales of H&N35.
In a one-factor model, four of the five sociodemographic
variables and four of the six clinical variables (except
CCI and the length of follow-up) were significantly (p <
0.05) associated with the overall outcome on H&N35. In
the multifactor model, only tumor site and RT techni-
que remained significant (Table 3).
The variables specifically associated with global QoL
and xerostomia were further analyzed. As demonstrated
by linear regression model in Table 4 we observed a sig-
nificant trend that survivors with CCI ≥ 1( b =5 . 2 ,p=
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treated by 2DRT (b=-12.2, p < 0.01) had a higher prob-
ability to report a high level of xerostomia. Meanwhile,
survivors with family annual income ≧1.2 million NTD
(b = 5.2, p < 0.01), CCI = 0 (b=-6.1, p < 0.01), or treated
by 3DCRTor IMRT (b = 7.7, p < 0.01) had a higher
probability of reporting a better global QoL.
Tumor site and HR-QoL outcome
Significant difference (p < 0.05) of HR-QoL outcome at
different tumor sites was observed at 11 of the 15 scales
i nQ L Q - C 3 0a n d1 0o ft h e1 3s c a l e si nH & N 3 5( T a b l e
5). Compared with nasopharyngeal cancer survivors,
three worse scales (social eating, social contact, and
opening mouth) were significantly observed on oral can-
cer survivors, so were six scales (appetite loss, pain,
swallowing, speech, social eating, and social contact) on
oropharyngeal cancer survivors and eight scales (physi-
cal functioning, role functioning, dyspnea, constipation,
swallowing, speech, social contact, coughing) on hypo-
pharyneal/laryngeal cancer survivors. Meanwhile, com-
pared with oral cavity survivors, five worse scales
(cognitive functioning, fatigue, nausea/vomiting, appetite
loss, and pain) were observed in oropharyngeal cancer
survivors, and five worse scales (physical functioning,
nausea/vomiting, dyspnea, speech, and coughing) in
hypopharyneal/laryngeal cancer survivors. On the con-
trast, better results in opening mouth and dry mouth
were observed in hypopharyneal/laryngeal cancer survi-
vors compared with the other survivors.
RT techniques and HR-QoL outcome
Significant difference (p < 0.05) of HR-QoL outcome by
different RT techniques was observed at 2 of the 15
scales in QLQ-C30 and 10 of the 13 scales in H&N35
(Table 6). Compared with 2DRT, IMRT had significant
better outcome in the scales of global QoL, physical
functioning, swallowing, senses (taste/smell), speech,
social eating, social contact, teeth, opening mouth, dry
mouth, sticky saliva, and feeling ill. Only three scales
(teeth, dry mouth, and sticky saliva) with better results
were observed in 3DCRT compared with 2DRT. IMRT
had better scores in most scales compared with 3DCRT,
but without reaching statistically significant difference.
Discussion
The treatment fields of conventional 2DRT for HNC are
usually large and anatomic structures situated nearby
the tumors, such as the salivary glands, inner ear, oral
cavity, and temporomandibular joints, are exposed to
almost the same irradiated dose as the treatment target
sites. We have previously used the Taiwan Chinese ver-
sion of SF-36 to investigate the HR-QoL of oral cancer
or nasopharyngeal survivors treated by conventional RT,
finding that these HNC survivors scored significantly
worse in most of the eight functional domains of SF-36
than Taiwanese norms [15,16]. However, SF-36 is not
specific and sensitive enough as a HR-QoL instrument
to discriminate the effect differences for head- and
neck-related problems between different treatment mod-
alities. In the present study, we used the EORTC QLQ-
C30 and H&N35 to assess HR-QoL for HNC patients.
The Taiwan Chinese version of the questionnaires has
been previously tested in HNC patients by Chie et al.
[23]. They found the Cronbach’s alpha coefficients of all
scales of the two questionnaires were ≧ 0.70, except that
for cognitive functioning, and the correlation of scales
that measure similar dimensions of the QLQ-C30 and
the SF-36 was moderate to high, whereas that of the
H&N35 and the QLQ-C30 or the SF-36 was moderate
to low.
Table 2 Calculated scores of EORTC QLQ-C30 and H&N35
scales for head and neck cancer survivors
Scales Mean (SD) Median Range
QLQ-C30
Global quality of life 54.6 (19.9) 50.0 0.0-100.0
Physical functioning 84.5 (16.5) 86.7 11.1-100.0
Role functioning 86.4 (21.0) 100.0 0.0-100.0
Emotional functioning 77.9 (20.0) 75.0 0.0-100.0
Cognitive functioning 78.4 (19.8) 83.3 0.0-100.0
Social functioning 75.1 (24.2) 66.7 0.0-100.0
Fatigue 29.2 (20.4) 33.3 0.0-100.0
Nausea/Vomiting 9.3 (17.5) 0.0 0.0-100.0
Pain 21.9 (22.4) 16.7 0.0-100.0
Dyspnea 15.2 (21.6) 0.0 0.0-100.0
Insomnia 26.3 (25.9) 33.3 0.0-100.0
Appetite loss 19.9 (24.6) 0.0 0.0-100.0
Constipation 19.1 (23.7) 33.3 0.0-100.0
Diarrhea 14.0 (19.9) 0.0 0.0-100.0
Financial problems 26.4 (27.1) 33.3 0.0-100.0
H&N35
Pain 19.1 (20.6) 16.7 0.0-100.0
Swallowing 30.2 (24.4) 25.0 0.0-100.0
Senses (taste/smell) 26.9 (27.7) 25.0 0.0-100.0
Speech 28.0 (25.9) 22.2 0.0-100.0
Social eating 28.5 (26.9) 25.0 0.0-100.0
Social contact 20.4 (23.5) 13.3 0.0-100.0
Sexuality 26.0 (27.7) 33.3 0.0-100.0
Teeth 38.9 (29.8) 33.3 0.0-100.0
Opening mouth 32.8 (31.6) 33.3 0.0-100.0
Dry mouth 48.3 (31.0) 33.3 0.0-100.0
Sticky saliva 40.7 (30.6) 33.3 0.0-100.0
Coughing 29.3 (25.4) 33.3 0.0-100.0
Feeling ill 29.3 (25.3) 33.3 0.0-100.0
Abbreviations: EORTC QLQ-C30: European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire C30; H&N35: Head and
Neck Module; SD: standard deviation.
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superiority of 3DCRT/IMRT applied in HNC patients
can not only preserve salivary functions, but also
improve local control, and even patient survival [10-12].
The current study presented with a large cohort to com-
pare HR-QoL between HNC survivors receiving differ-
ent RT techniques applied at a single institute during
different time periods, adjusting for major sociodemo-
graphic and medical variables that affect these measures.
Although heterogeneity existed in the comparing
groups, the potential bias of patient selection was
reduced, and the contributions of the different RT tech-
niques in producing particular HR-QoL outcomes were
highlighted. We demonstrated that the use of IMRT sig-
nificantly improved HR-QoL for HNC survivors as com-
pared with those treated by conventional 2DRT.
Xerostomia related symptoms were usually cited as
the most prevalent complications in HNC survivors post
RT and patient-reported xerostomia has been found to
significantly correlate with mean dose to the parotid
Table 3 GLM-MANOVA test of the overall effect of the sociodemographic and clinical variables on the EORTC QLQ-C30
and H&N35 scales
QLQ-C30 QLQ-H&N35
One-factor
model*
Multifactor
model**
One-factor
model*
Multifactor
model**
Variable Wilk’s l p Wilk’s l p Wilk’s l p Wilk’s l p
Sociodemographic variables
Age: <40 v 40~60 v ≥ 60 years 0.922 0.016 0.942 NS 0.926 0.013 0.939 NS
Gender: female v male 0.890 <0.01 0.877 <0.01 0.919 0.018 0.963 NS
Education years: ≤ 6 v 6~12 v >12 0.914 0.011 0.928 NS 0.920 0.033 0.941 NS
Marital status: with v without spouse 0.958 0.042 0.951 NS 0.975 NS 0.968 NS
Annual family income: < 0.6 v 0.6~1.2 v ≥ 1.2 (million NTD) 0.845 <0.01 0.896 0.032 0.866 <0.01 0.910 NS
Clinical variables
CCI score: 0 v ≥ 1 0.937 0.001 0.910 NS 0.965 NS 0.935 NS
Tumor site: Oral cavity v Oropharynx v Hypopharynx/Larynx v Nasopharynx 0.805 <0.01 0.828 <0.01 0.618 <0.01 0.824 <0.01
AJCC stage: stage I-II v III-IV 0.870 <0.01 0.863 <0.01 0.880 <0.01 0.869 NS
Treatment methods: S + RT v S + RT+ C/T v RT±C/T 0.865 <0.01 0.845 <0.01 0.832 <0.01 0.906 NS
RT technique: 2DRT v 3DCRT v IMRT 0.888 <0.01 0.876 <0.01 0.869 <0.01 0.829 <0.01
Follow-up years: 2~3 v 3~5 v > 5 0.937 NS 0.928 NS 0.933 NS 0.938 NS
*: The one factor model: only one independent variable was entered into the model. **: The multifactor model: all mentioned variables were entered as
independent variables in the model. Abbreviations: GLM-MANOVA: general linear model multivariate of variance; EORTC QLQ-C30: European Organization for
Research and Treatment of Cancer Quality of Life Core questionnaire; H&N35: Head and Neck Module; NTD: New Taiwan Dollar (1 USD = 33 NTD); CCI: Charlson
comorbidity index; AJCC: American Joint of Cancer Committee published in 2002; S: surgery; RT: radiotherapy; C/T: chemotherapy; 2DRT: two dimensional RT;
3DCRT: three dimensional conformal RT; IMRT: intensity modulated RT; NS: not significant.
Table 4 Multiple linear regression analysis for global quality of life and xerostomia
Xerostomia Global quality of life
Variable b SE p b SE p
Sociodemographic variables
Age: <40 v 40~60 v ≥60 years -0.7 2.5 NS -0.2 1.6 NS
Gender: female v male -1.7 3.5 NS 0.5 2.2 NS
Education years: ≤ 6 v 6~12 v >12 1.2 3.6 NS 3.2 1.3 NS
Marital status: with v without spouse -2.6 3.1 NS -3.0 2.0 NS
Annual family income: <1.2 v ≥1.2 (million NTD) -4.0 2.5 NS 5.2 1.6 <0.01
Clinical variables
CCI score: 0 v ≥ 1 5.2 2.5 0.034 -6.1 1.6 <0.01
Tumor site: Nasopharynx v others -9.1 4.3 0.036 -0.9 2.7 NS
AJCC stage: stage I-II v III-IV 1.5 3.1 NS 0.2 2.0 NS
Treatment methods: S + RT v S + RT+ C/T v RT±C/T 3.0 3.7 NS -1.8 2.3 NS
RT technique: 2DRT v 3DCRT/IMRT -12.2 2.7 <0.01 7.7 1.7 <0.01
Follow-up years: 2~3 v 3~5 v > 5 0.2 2.9 NS 1.6 1.9 NS
b: un-standardized regression coefficient; SE: standard error; R2 = 0.072 in the model for xerostomia; R2 = 0.077 in the model for global quality of life; NTD: New
Taiwan Dollar (1 USD = 33 NTD); CCI: Charlson comorbidity index; AJCC: American Joint of Cancer Committee published in 2002; S: surgery; RT: radiotherapy; C/T:
chemotherapy; 2DRT: two dimensional RT; 3DCRT: three dimensional conformal RT; IMRT: intensity modulated RT; NS: not significant.
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Page 6 of 10glands and the minor salivary glands in the oral cavity
[26]. In a matched comparison of 67 pairs of HNC sur-
vivors treated by 2DRT versus IMRT, Graff et al.
observed the major advantages of IMRT were on oral
symptoms, especially salivary dysfunction and oral dis-
comfort [27]. Similarly, a cross sectional survey of 163
HNC survivors by van Rij et al. also revealed that paro-
tid sparing IMRT for HNC patients improved xerosto-
mia related HR-QoL compared to 2DRT both in rest
and during meals [28]. With the large cohort of 640
HNC survivors in current study, we confirmed that RT
technique is the determining variable affecting xerosto-
mia in HNC survivors and affirmed that modern RT,
especially for IMRT, not only reduced the oral related
symptoms but also the global QoL.
However, the direct cause-effect relationship between
xerostomia and broad aspect of HR-QoL in HNC
patients after RT has not been established yet. The
improvement of IMRT in HR-QoL might not be only
through reducing xerostomia by salivary glands sparing,
but also reducing the volume of other non-target organs
receiving a high dose. Some reports have shown that
radiation-induced dysphagia also plays an important role
in HR-QoL domains [28-30]. Dysphagia is usually multi-
factorial and strongly associated with xerostomia. It has
become increasingly important to identify the anatomi-
cal structures that are involved in swallowing problems
after RT. A cross-sectional study of 81 patients with
oropharyngeal cancer, reported by Levendag et al.,
showed that the probability of swallowing complaints is
Table 5 The comparisons of EORTC QLQ-C30 and H&N35 scales for head and neck cancer survivors at different
tumor sites
Nasopharynx
(n = 316)
Oral cavity
(n = 129)
Oropharynx
(n = 75)
Hypropharynx
&Larynx(n = 120)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) p
EORTC QLQ-C30
Global quality of life 53.7 (20.4) 56.1 (16.7) 55.2 (21.6) 54.8 (20.9) NS
Physical functioning 85.7 (16.3) 86.4 (13.8)e 82.2 (16.9) 80.9 (18.7)c 0.015
Role functioning 88.7 (19.5) 87.0 (19.1) 83.6 (22.1) 81.2 (25.0)c <0.01
Emotional functioning 78.0 (19.7) 79.9 (18.6) 75.3 (22.7) 77.0 (20.8) NS
Cognitive functioning 77.8 (18.7) 82.8 (19.2)d 75.1 (23.0) 76.9 (20.9) 0.025
Social functioning 77.0 (23.2) 75.4 (22.8) 73.1 (27.0) 71.0 (25.8) NS
Fatigue 29.6 (19.8) 24.9 (21.2)d 32.7 (19.2) 30.4 (21.4) 0.037
Nausea/Vomiting 8.4 (15.6) 6.2 (14.2)d, e 13.5 (22.5) 12.4 (20.8) <0.01
Pain 20.8 (21.5) 19.2 (23.1) 26.8 (21.9) 24.9 (23.8) 0.038
Dyspnea 12.7 (19.9) 12.4 (20.4)e 17.8 (23.5) 23.6 (24.0)c <0.01
Insomnia 25.1 (26.3) 23.1 (25.5) 30.1 (22.8) 30.7 (26.5) 0.049
Appetite loss 17.0 (23.8) 17.9 (24.3)d 30.7 (26.0)b 23.1 (24.1) <0.01
Constipation 16.5 (22.4) 18.4 (22.4) 23.7 (26.8) 24.0 (25.3)c <0.01
Diarrhea 13.4 (18.9) 12.2 (18.6) 16.4 (26.0) 15.9 (19.3) NS
Financial problems 23.4 (26.4) 26.9 (25.7) 31.9 (29.9) 30.5 (27.9) 0.023
EORTC QLQ-HN35
Pain 17.0 (18.3) 17.3 (22.9)d 27.4 (20.7)b 21.5 (22.5) <0.01
Swallowing 26.8 (22.4) 30.6 (25.4) 38.0 (23.6)b 33.8 (27.5)c <0.01
Senses (taste/smell) 27.2 (27.0) 22.1 (26.8) 26.4 (27.4) 31.3 (30.1) NS
Speech 23.0 (23.3) 25.6 (21.8)e 32.0 (27.1)b 41.3 (30.7)c <0.01
Social eating 24.1 (24.9) 33.2 (27.0)a 35.4 (27.8)b 30.7 (29.5) <0.01
Social contact 15.4 (19.9) 24.0 (23.2)a 23.9 (26.7)b 27.5 (27.4)c <0.01
Sexuality 23.8 (27.6) 24.3 (24.4) 30.5 (29.4) 31.3 (29.5) 0.035
Teeth 38.1 (28.3) 41.0(31.8) 42.7 (30.2) 36.1 (31.3) NS
Opening mouth 30.1 (29.7) 43.9 (34.2)a, e 37.8 (32.9)f 25.1 (29.4) <0.01
Dry mouth 53.5 (31.3) 45.9 (30.7) 49.2 (30.6)f 36.6 (27.5)c <0.01
Sticky saliva 42.8 (31.7) 37.6 (28.4) 46.3 (29.8) 35.0 (29.8) 0.024
Coughing 25.9 (23.9) 23.9 (23.3)e 31.5 (27.4)f 43.1 (25.4)c <0.01
Feeling ill 29.6 (25.5) 24.8 (23.7) 31.5 (25.1) 32.1 (26.0) NS
a : p < 0.05, Oral cavity compared with Nasopharynx; b : p < 0.05, Oropharynx compared with Nasopharynx; c : p < 0.05, Hypropharynx & Larynx compared with
Nasopharynx; d : p < 0.05, Oral cavity compared with Oropharynx; e : p < 0.05, Oral cavity compared with Hypropharynx & Larynx; f : p < 0.05, Oropharynx
compared with Hypropharynx & Larynx.
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Page 7 of 10significantly associated with the mean total radiation
dose in the superior and middle pharyngeal constrictor
muscle [29]. Our data confirmed this hypothesis that
the use of 3DCRT/IMRT also reduced other head-and-
neck-related symptom scales to some extent. The inter-
and intra-scale correlations of EORTC QLQ-C30 and
QLQ-H&N35 were significantly high in our series [data
not shown], which means the symptomatic problems
improved by 3DCRT/IMRT are inter-correlative and
might converge and reflect to the expression of patients’
global QoL.
The comparisons between 3DCRT and IMRT were
mainly on the dosimetric distribution in the literature,
and the information concerning the clinical advantage
attributed to the evolution from 3DCRT to IMRT in
HNC patients is still limited and controversial. In our
previous study exclusively focusing on nasopharyngeal
cancer, a significant reduction of 25-30% of the mean
dose to the normal structures such as parotid glands
and oral cavity was created by IMRT compared with
3DCRT. However, comparing their longitudinal changes
of HR-QoL, we did not find a significant difference at
most time points except 3 months after RT [31]. Cur-
rent study echoes this finding that the positive advan-
tage of IMRT over 3DCRT in QoL is ambiguous and
marginal in HNC survivors. In contrast, a non-rando-
mized prospective comparison between HNC patients
treated by 3DCRT or IMRT demonstrated that IMRT
resulted in a significant reduction of patient- and obser-
ver-rated xerostomia, as well as other head and neck
symptoms, compared with standard 3DCRT [32]. With
locally advanced disease treated by aggressive combined
Table 6 The comparisons of EORTC QLQ-C30 and H&N35 scales for head and neck cancer survivors by different RT
techniques
2DRT
(n = 371)
3DCRT
(n = 127)
IMRT
(n = 142)
Mean (SD) Mean (SD) Mean (SD) p
EORTC QLQ-C30
Global quality of life 51.7 (19.9) 56.2 (18.6) 60.7 (19.7)b, <0.01
Physical functioning 83.1 (17.7) 86.2 (14.1) 86.7 (14.6)b 0.039
Role functioning 85.6 (22.2) 86.7 (19.4) 88.1 (19.1) NS
Emotional functioning 76.6 (20.8) 79.8 (18.0) 79.6 (19.8) NS
Cognitive functioning 77.2 (20.7) 79.9 (16.6) 80.0 (20.1) NS
Social functioning 73.4 (26.0) 76.7 (20.3) 78.1 (22.0) NS
Fatigue 31.0 (21.1) 26.9 (16.8) 26.5 (21.0) NS
Nausea/Vomiting 10.3 (19.2) 7.7 (13.6) 8.2 (15.5) NS
Pain 23.9 (24.1) 18.5 (16.9) 19.7 (21.7) NS
Dyspnea 16.2 (23.4) 15.8 (18.8) 12.1 (18.7) NS
Insomnia 26.9 (27.5) 25.6 (22.1) 25.4 (25.0) NS
Appetite loss 21.7 (26.7) 18.8 (20.9) 16.4 (21.2) NS
Constipation 19.8 (25.2) 19.2 (22.5) 17.1 (20.4) NS
Diarrhea 14.8 (21.3) 12.4 (17.8) 13.3 (17.6) NS
Financial problems 27.1 (28.1) 23.1 (24.1) 27.6 (26.7) NS
EORTC QLQ-HN35
Pain 20.8 (22.6) 18.4 (16.7) 15.2 (17.7) NS
Swallowing 33.3 (25.6) 28.0 (22.4) 23.9 (21.5)b <0.01
Senses (taste/smell) 29.4 (29.0) 26.3 (28.1) 20.6 (22.7)b <0.01
Speech 29.6 (26.4) 29.5 (25.7) 22.4 (24.0)b 0.013
Social eating 31.0 (27.5) 28.5 (27.0) 21.9 (24.3)b <0.01
Social contact 21.0 (24.1) 22.7 (24.7) 16.6 (20.3)b <0.01
Sexuality 27.4 (28.9) 27.0 (28.0) 21.5 (23.8) NS
Teeth 43.2 (30.6) 34.7 (29.1)a 31.2 (26.0)b <0.01
Opening mouth 36.5 (31.7) 30.2 (30.4) 25.4 (31.1)b <0.01
Dry mouth 54.0 (31.9) 43.8 (28.2)a 41.0 (27.9)b <0.01
Sticky saliva 45.1 (32.3) 35.8 (26.1)a 33.6 (27.9)b <0.01
Coughing 31.0 (26.9) 29.5 (24.2) 24.5 (21.7) NS
Feeling ill 32.3 (26.3) 26.3 (23.0) 24.0 (23.2)b <0.01
Abbreviations: RT = radiotherapy; 2DRT = two dimensional RT; 3DCRT = three dimensional conformal RT; IMRT = intensity-modulated RT; a: p < 0.05, 3DCRT
compared with 2DRT; b: p < 0.05, IMRT compared with 2DRT
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Page 8 of 10modality in most of our subjects, we found that the
dosimetric improvement for 3DCRT compared with
IMRT might not be sufficiently large to demonstrate
any significant difference in HR-QoL.
Besides radiation technique, socioeconomic status,
comorbidity, and tumor site were also found to be sig-
nificant prognosticators on HR-QoL outcome. With the
relatively heterogeneous nature of HNC patients and
experienced treatments including varying tumor stages,
sites, and the frequently diverse treatment modalities
applied and involved administering institutions, the fac-
tors affecting the HR-QoL after treatment for HNC
patients usually appear to be somewhat discordant and
complicated in the literature. For example, Hammerlid
et al. found those HNC survivors with tumor located at
larynx, aged below 65 years, or female patients had sig-
nificantly better HR-QoL than their counterparts three
years after treatment [33] and de Graeff et al. reported
female sex, higher cancer stage, and combination treat-
ment were found to be associated with more sympto-
matic problems and worse HR-QoL [34].
Although being comprehensive and well validated
with recognized internal consistency and reliability,
EORTC QLQ-C30 and QLQ-H&N35 still have some
limitations in the interpretation of HR-QoL of HNC
patients, because they do not deal with some specific
but common late sequelae, such as deafness, otitis
media, symptoms from temporal lobe necrosis, or
radiation neuropathy, or hypopituitarism in nasophar-
yngeal cancer survivors. A tumor site-specific assess-
ment tool of HR-QoL might provide more specific and
sensitive information to discriminate site-related differ-
ences of HR-QoL in HNC patients with various tumor
sites treated by different strategies. Furthermore, with-
out pre-treatment HR-QoL data available in our
cohort, potential selection bias might still exist in the
cross sectional study, though the confounding variables
adjusted by multivariate analysis. A longitudinal study
assessing the changes of HR-QoL will be justified to
more accurately detect the differences between the
groups.
Conclusions
With the advance of modern RT technology, head-and-
neck related symptoms after RT could be significantly
reduced and reflected to the improvement of broad
aspects of HR-QoL in HNC survivors. However, there
may still be some undetected factors, which are related
to global QoL or some specific functional domains, to
be explored in future investigation.
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